​mRNA Technology: Where Science Meets the Next Wave of Life Science Investment

​Welcome to a focused session for investors exploring the next wave of mRNA innovation - from new therapeutic applications and AI-driven drug discovery to emerging market opportunities.

​The global mRNA vaccine and therapeutics market is projected to reach USD 68.1 billion by 2030, growing at 8.8% to 13.2% annually. Once known mainly for infectious disease vaccines, mRNA is now expanding into oncology, autoimmune disease, and pandemic preparedness. Investors who understand this shift early stand to benefit the most.

​The Life Science Cluster, together with Framdrift, invites investors to a focused session designed to cut through the complexity: where the science is heading, how big the opportunity could be, and what it takes to evaluate this space with confidence.

​Speakers from science and technology backgrounds will cover the science driving this transformation, the AI powered platforms accelerating drug discovery, and the market dynamics shaping where capital is flowing next. This is a strategic briefing built for investors, with or without a scientific background, who want a real edge in understanding this space.

​The event takes place at Framdrift, Bergen’s newly established venue.

​Seats are limited to keep the discussion focused and give you direct access to the speakers.

​Agenda

​Moderator: TBA

​16.00-16.10: Welcome, Delphine Costa (TLSC)

​16.10-16.32: Investing in Life Sciences What it takes to back the next breakthrough, Lars Mørland Knudsen (P53) & Øyvind Kongstuen (OCC)

​16.32-16.44: Founder(s) on Stage Company pitches: companies pitch their path to market, Peter W. Eide & Jarle Bruun (Oncosyne)

​16.44-16.54: Q&A with the Founders. Open to questions from the audience and investors

​16.54-17.16: Inside Revolution Medicines, Benedicte Bakken (DNB)

​17.16-17.38: Next Generation of Vaccines How vaccine innovation is evolving beyond COVID, Arun Kumar (CEPI)

​17.38-17.55: Fireside Chat Reflections on mRNA vaccine treatment, Kristin Mohn (Haukeland University Hospital) & Kristin Odfjell (Farvatn)

​17.55-18.00: Closing Thoughts, Shokouh Makvandi-Nejad (TLSC)houghts, Shokouh Makvandi-Nejad (TLSC)